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SUMMARY
The androgen receptor (AR) plays a critical role in prostate cancer. We have identified a ubiquitin E3 ligase,
RNF6, as an AR-associated protein in a proteomic screen. RNF6 induces AR ubiquitination and promotes
AR transcriptional activity. Specific knockdownofRNF6ormutation ofRNF6-inducedubiquitination acceptor
sites on AR selectively alters expression of a subset of AR target genes and diminishes recruitment of AR and
its coactivators to androgen-responsive elements present in the regulatory region of these genes. Further-
more, RNF6 is overexpressed in hormone-refractory human prostate cancer tissues and required for prostate
cancer cell growth under androgen-depleted conditions. Our data suggest that RNF6-induced ubiquitination
may regulate AR transcriptional activity and specificity through modulating cofactor recruitment.INTRODUCTION
The androgen receptor (AR) is the key transcription factor medi-
ating androgen-induced signaling, which is required for prostate
cell survival and proliferation. It is well accepted that AR plays an
important role in development of prostate cancer as well as
progression to androgen-independent disease (Chen et al.,
2004; Zegarra-Moro et al., 2002). Like other members of the
steroid hormone nuclear receptor superfamily, AR is translo-
cated into the nucleus upon ligand stimulation and binds to
specific DNA sequences known as androgen-responsive
elements (AREs), where it recruits the basic transcription
machinery as well as the cofactors to modulate the transcription
of androgen-responsive genes (Agoulnik and Weigel, 2006).Several recent studies have suggested that AR may preferen-
tially recognize different AREs in different cell contexts and in
response to different extracellular stimuli (Bolton et al., 2007;
Guo et al., 2006). The different cofactor repertoire and posttrans-
lational modifications of AR as well as local chromatin modifica-
tions of the target genes may play a role in the regulation of AR
transcriptional activity and specificity. As a key regulator of
prostate homeostasis, AR activity is precisely modulated at
multiple levels, including posttranslational modifications such
as phosphorylation, acetylation, sumoylation, and ubiquitination
(Faus and Haendler, 2006; Gregory et al., 2004; Guo et al., 2006;
Lin et al., 2002; Mahajan et al., 2007; Ueda et al., 2002).
Ubiquitination is one of the most abundant protein modifica-
tions in eukaryotic cells, and it has emerged as a vital mediatorSIGNIFICANCE
The androgen receptor (AR) is the key transcription factor mediating androgen signaling in prostate cells. Androgen ablation
therapy is the most common treatment for advanced prostate cancer. However, most patients inevitably develop deadly
recurrent cancers, which are resistant to current therapy. In this study, we show that RNF6 is overexpressed in
hormone-resistant prostate cancer and induces ubiquitination of AR to promote its transcriptional activity toward a subset
of AR target genes under androgen-depleted conditions. Our work suggests that ubiquitination of AR, and possibly other
transcription factors, may function as the scaffold for cofactor recruitment to modulate transcriptional activity and
specificity. Targeting components of the ubiquitination machinery, such as RNF6, may potentially be effective in treatment
of advanced prostate cancer.
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RNF6 Regulates AR Transcriptional Activityfor a broad range of intracellular signaling activities, such as
proteasomal degradation, endocytosis, subcellular localization,
and kinase activation (Haglund and Dikic, 2005). Its involvement
in versatile cellular functions possibly comes from the fact that
the ubiquitin (Ub) molecule can form chains on substrates with
various lengths and can elongate at different lysine (K) residues
within the ubiquitin molecule. All seven conserved lysine resi-
dues within ubiquitin can mediate polyubiquitin chain formation
(Kim et al., 2007), and different types of branching chains have
distinct biological effects (Chastagner et al., 2006; Hofmann
and Pickart, 1999; Morris and Solomon, 2004). For example,
K48-branched chains are well accepted as the signals for
proteasome degradation, while K6-mediated polyubiquitin
chains can protect the substrates from proteolysis (Shang
et al., 2005). K63 linkages, however, mainly have nonproteolytic
functions such as DNA repair (Spence et al., 1995), kinase acti-
vation (Deng et al., 2000), and endocytosis (Bonifacino and
Weissman, 1998). The attachment of multiple ubiquitin moieties
is mediated via a three-step mechanism involving the sequential
actions of E1, E2, and E3 enzymes (Hershko and Ciechanover,
1998; Pickart and Eddins, 2004). The ubiquitin chain topology
is believed to be tightly controlled, and at least two different
classes of E2 are required to attach a polyubiquitin chain of
a particular topology to a substrate. The first E2 monoubiquiti-
nates the acceptor lysine residue of the substrate; the second
E2 elongates a polyubiquitin chain using a defined lysine residue
of ubiquitin in concert with a specific E3 ligase (Kim et al., 2007;
Rodrigo-Brenni and Morgan, 2007; Windheim et al., 2008).
Regulation of AR nuclear trafficking and activity by the ubiquitin
system has been studied previously (Poukka et al., 2000; Verma
et al., 2004), but detailed mechanisms remain obscure. Recent
evidence has shown that the E3 ligase MDM2 can induce poly-
ubiquitination of AR, which leads to AR degradation via the
26S proteasome (Lin et al., 2002). This modification reduces
the steady-state level of AR and attenuates AR transcriptional
activity as well as androgen/AR-mediated cell growth. However,
modulation of androgen/AR signaling by ubiquitination may not
be limited to regulation of protein turnover, as the ubiquitin
system has been reported to directly regulate the transcriptional
activity of p53 independently of protein degradation (Le Cam
et al., 2006). It has yet to be determined whether such a mecha-
nism may be applicable in regulation of AR activity.
In a search for AR-associated proteins in prostate cancer cells,
we identified a RING domain-containing E3 ligase, RNF6. RNF6
was originally cloned in a genetic study of chromosomal rear-
rangements in myeloproliferative disorders, mapping to chromo-
some 13q12.12 (Macdonald et al., 1999). It encodes a 685 amino
acidprotein containingacoiled-coil domain at theN terminusand
a RING-H2 finger at the C terminus that is responsible for its ubiq-
uitin ligaseactivity. Themurinehomologof humanRNF6hasbeen
demonstrated toactivate Inhageneexpressionbyparticipating in
a protein complex binding to the promoter region (Lopez et al.,
2002). A recent study demonstrated that the serine/threonine
kinase LIM kinase 1 (LIMK1) is a substrate of RNF6 and that
RNF6-induced LIMK1 polyubiquitination is mediated via K48 of
ubiquitin, leading to proteasomal degradation of the kinase
(Tursun et al., 2005). In the current study, we intended to examine
the mechanisms by which RNF6 may regulate AR transcriptional
activity and its potential role in prostate cancer progression.RESULTS
RNF6 Is Associated with AR in Prostate Cancer Cells
To search for AR-interacting proteins in hormone-refractory
CWR-R1 prostate cancer cells, we performed in vitro GST pull-
down assays using the GST fusion protein containing the AR
C-terminal region (aa 622–919) (GST-ARc). Among a number of
proteins that specifically bound to AR but not to the GST control,
RNF6 was one of the top scored proteins identified by mass
spectrometry (MS) analysis (Figure 1A). The interaction between
AR and RNF6 was confirmed by reciprocal coimmunoprecipita-
tion experiments in 293T cells overexpressing both AR andRNF6
(Figure 1B). In addition, the association of endogenous RNF6
with AR was enhanced by androgen treatment in the prostate
cancer cell lines CWR-R1 and LNCaP (Figure 1C). Immunofluo-
rescence staining revealed that endogenous AR and RNF6
were colocalized in punctate structures spreading throughout
in the nucleus (Figure 1D). It is well known that active transcrip-
tion foci are distributed in the nucleus in a punctate pattern;
therefore, RNF6 and AR may form a complex to regulate tran-
scription in prostate cancer cells.
RNF6 Induces Ubiquitination of AR
To test whether AR is a substrate of RNF6, AR and HA-tagged
wild-type RNF6 or a mutant lacking the RING domain
(HA-RNF6DR) were coexpressed in COS-1 cells. Another known
AR E3 ligase, MDM2, was included as a positive control. As
shown in Figure 2A, accumulation of ubiquitinated AR was
detected in cells expressing either RNF6 or MDM2, but not in
cells expressing inactive mutant HA-RNF6DR or MDM2-
C464A, suggesting that both RNF6 and MDM2 can induce AR
ubiquitination in a RING domain-dependent manner. Consistent
with previous studies, the steady-state level of AR in cells coex-
pressing wild-type MDM2 was dramatically reduced compared
to that in cells expressing AR alone or that in cells coexpressing
MDM2-C464A mutant as a result of polyubiquitination-associ-
ated proteasomal degradation. However, AR protein level was
not decreased in cells overexpressing RNF6, suggesting that
these two ubiquitin ligases have distinct effects on AR stability
and that RNF6-induced AR ubiquitination appears not to be
involved in AR degradation. The in vitro ubiquitination assays
suggested that AR might be a direct substrate of RNF6, as the
higher-molecular-weight polyubiquitinated AR was detected
only in the presence of the active RNF6 (Figure 2B). We then
examinedwhich lysine residue (or residues) in the ubiquitinmole-
cule might be involved in assembly of the atypical polyubiquitin
chains on AR induced by RNF6. AR andRNF6were coexpressed
with His-tagged ubiquitin, a ubiquitinmutant without lysines (K0),
or ubiquitinmutants with a single lysine in COS-1 cells. It appears
that when overexpressing His-Ub in cells, the transfected AR is
heavily mono- or oligoubiquitinated even in the absence of exog-
enous RNF6, possibly due to the activity of some endogenous E2
or E3 ligases. Addition of RNF6 seemed to have little effect on
mono-Ub or oligo-Ub AR but did significantly enhance polyubi-
quitination of AR in the presence of wild-type Ub, Ub-K6, and
possibly Ub-K27, suggesting that RNF6 may preferentially
assemble polyubiquitination chains at K6 and K27. This was sup-
ported by the in vitro ubiquitination assays shown in Figure 2D.
Although all single-K Ub mutants were able to be conjugated inCancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc. 271
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RNF6 Regulates AR Transcriptional Activitythe mono- or di-Ub ARc, only the Ub-K6 and Ub-K27 mutants
could assemble detectable poly-Ub chains on ARc under our
experimental conditions. These data suggest that only K6 and/
or K27 are able to assemble polyubiquitin chains on AR protein
in the presence of RNF6. The atypical polyubiquitin chain has
recently been reported to have a nonproteolytic effect on its
target proteins (Ben-Saadon et al., 2006). This finding may help
to explain our observation that RNF6-induced ARpolyubiquitina-
tion does not lead to its destabilization.
RNF6 Modulates AR Transcriptional Activity
and Specificity
It is well known that androgens induce transactivation of AR in
prostate cancer cells. Interestingly, a dramatic increase in ubiq-
uitination of AR was also observed in CWR-R1 and LNCaP cells
treated with the synthetic androgen R1881, suggesting that
ubiquitination of AR is accompanied by its activation (see
Figure S3 available online). Consistent with our earlier observa-
tion that RNF6 induces AR ubiquitination, knockdown of endog-
enous RNF6 in these cells significantly diminished both basal
and androgen-induced ubiquitination of AR (Figure 3A), implying
Figure 1. RNF6 Interacts with the Androgen
Receptor in Prostate Cancer Cells
(A) Left: GST pull-down assays were performed
using GST or GST-ARc as described in Experi-
mental Procedures. Bound proteins were eluted
and resolved by SDS-PAGE and then visualized
by Coomassie blue staining. Discrete bands
were excised and subjected to tryptic digestion
and matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) analysis. M, marker;
GST-ARc, GST-AR fusion protein containing
residues 622–919 of the androgen receptor (AR).
Arrow indicates the band in which RNF6 was
identified. Right: protein sequence of RNF6, with
matched peptides shown in bold red.
(B) 293T cells were transfected with AR, RNF6, or
both. At 48 hr posttransfection, cells were lysed
and immunoprecipitation was performed using
anti-AR or anti-RNF6 antibody, followed by immu-
noblotting with the indicated antibodies.
(C) CWR-R1 and LNCaP cells were subjected to
immunoprecipitation using control IgG or anti-
RNF6. Immunoblotting was performed using
either precipitated samples or total cell lysates
(TCL) with the indicated antibodies.
(D) Confocal immunofluorescence microscopy
was carried out by costaining CWR-R1 cells with
anti-AR (red) and anti-RNF6 (green) antibodies.
Nuclei were counterstained with DAPI. Scale
bar = 1 mm.
that RNF6 may modulate AR transcrip-
tional activity via ubiquitination under
both androgen-responsive and
androgen-depleted conditions. To test
whether RNF6 is involved in AR activa-
tion, we examined the effects of RNF6
knockdown on AR transcriptional activity
in LNCaP and CWR-R1 cells using ARR2-
LUC reporter as a readout. As shown in
Figure 3B, dihydrotestosterone (DHT)-induced AR activation
was dramatically inhibited by RNF6 shRNA in these cells,
suggesting that RNF6 is required for transactivation of AR in
response to androgen. It should be noted that in the absence
of androgen or in the presence of a low level of androgen
(0.1 nM), AR activity was also significantly reduced in RNF6
knockdown CWR-R1 cells (p < 0.01), suggesting that RNF6
may also be required for AR transcriptional activity under
androgen-depleted conditions. This result was further supported
by the observation that knocking down endogenous RNF6 in
CWR-R1 and C4-2B cells under serum-free conditions dimin-
ished the expression level of a well-established AR target gene
product, prostate-specific antigen (PSA), concurrent with the
reduction of AR ubiquitination (Figure 3C). In addition, an
increase in RNF6 protein level was detected in the hormone-
insensitive LNCaP derivative C4-2B compared to its parental
line LNCaP (Figure S4A). This is consistent with a report in
a publicly available microarray database showing a 2- to 3-fold
increase in RNF6 mRNA in C4-2 cells compared to LNCaP cells
(Figure S4B). Overexpression of AR with RNF6, but not with
RNF6DR, induced approximately 2- to 3-fold higher activity of272 Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc.
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RNF6 Regulates AR Transcriptional Activitythe PSA promoter in COS-1 cells (Figure 3D). A similar enhance-
ment of endogenous AR transcriptional activity was also
observed in LNCaP cells (Figure 3E). Taken together, these
results demonstrate that RNF6 modulates AR transcriptional
activity under hormone-deprived conditions.
To examine the global effect of RNF6 on gene transcription in
prostate cancer cells, RNF6 expression was knocked down in
LNCaP cells by specific shRNA, and microarray analysis was
performed to determine altered gene profiling. As shown at left
in Figure 3F, knockdown of RNF6 in LNCaP cells induced
profound global changes in gene expression in response to
androgen. Expression of some of genes was upregulated while
expression of others was downregulated, suggesting that
RNF6 may function as a general transcriptional regulator (either
repressor or activator) depending on promoter context. Many
androgen-responsive genes are known to be regulated by AR
(Figure 3F, right). Knockdown of RNF6 had dramatic effects on
expression of a subset of these genes, including PPAP2A,
TMEPAI, RLN1, KLK3, NKX3.1, and BMF, suggesting that
RNF6 may modulate AR transcriptional activity on these target
genes. Meanwhile, inhibition of RNF6 appeared to have little or
Figure 2. RNF6 Induces Atypical Polyubi-
quitination of AR
(A) COS-1 cells were transfected with plasmids as
indicated. At 36 hr, cells were lysed and subjected
to immunoprecipitation using anti-AR under dena-
turing conditions, followed by immunoblotting with
the indicated antibodies.
(B) In vitro ubiquitination assays were carried out
as described in Experimental Procedures. Top:
immunoblot of anti-AR to detect AR and AR conju-
gates. Bottom: Coomassie blue staining (CBS) of
the gel to monitor the amount of E3 ligases present
in the reactions.
(C) COS-1 cells were transfected with His6-tagged
wild-type (WT) ubiquitin, a lysine null mutant (K0),
or a single-lysine-containing mutant as indicated,
along with FLAG-AR and HA-RNF6. At 36 hr post-
transfection, cells were lysed, and lysates were
incubated with Ni-NTA beads rotating at 4C for
overnight. Immunoblotting was performed using
the indicated antibodies.
(D) In vitro ubiquitination assays were carried out
as in (B), except that ubiquitin was replaced with
the lysine null mutant (K0) or a single-lysine-
containing mutant as indicated.
no effect on another subset of AR target
genes including PDIA5, SLC45A3,
TMPRSS2, and SORD. A similar change
induced by shRNF6 was observed in
cells without DHT treatment, suggesting
that RNF6 may also modulate the basal
activity of AR under androgen-depleted
conditions. To test whether the altered
gene expression was mediated via AR,
we examined the effects of RNF6 knock-
down on AR recruitment to the regulatory
region of these genes. Consistent with
themicroarray data, the chromatin immu-
noprecipitation (ChIP) assays shown in Figure 3G demonstrated
that knockdown of RNF6 in LNCaP abolished AR recruitment to
a subset of AREs (including those located in the enhancer region
of PSA [AREIII] and the promoter region of RLN1 and BMF) but
had little effect on the other subset of AREs such as those in
the promoter region of PSA (AREI/II) and TMPRSS2. Thus,
RNF6 may modulate the specificity of AR-mediated transcrip-
tion, and overexpression of RNF6 in prostate cancer cells may
preferentially modulate a subset of AR target genes, such as
RLN1 (relaxin 1), to promote progression to an androgen-inde-
pendent state. In addition, we performed reChIP assays using
anti-RNF6 following the anti-AR antibody. As shown in
Figure 3H, RNF6 appeared to be detectable in the AR-containing
protein complex assembled on the ARE sites in the regulatory
regions of PSA (AREIII), RLN1, and BMF but not present in the
complex on the ARE sites of PSA (AREI/II) and TMPRSS2.
To further investigate how RNF6-induced ubiquitination
modulates AR activity, we set out to identify the ubiquitin
acceptor sites in AR. Our tandem MS analysis revealed that
two lysine residues, K845 and K847, were ubiquitinated in
samples derived from cells expressing AR and RNF6Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc. 273
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RNF6 Regulates AR Transcriptional ActivityFigure 3. RNF6 Modulates AR Transcriptional Activity and Specificity
(A) CWR-R1 and LNCaP cells were infected with lentiviruses encoding shRNAs for control vector (shCon) or RNF6 (shRNF6). After serum starvation, cells
were pretreated with 10 nM R1881 for 16 hr. Cells were then lysed and subjected to immunoprecipitation with anti-AR under denaturing conditions, followed
by immunoblotting with the indicated antibodies.
(B) CWR-R1 and LNCaP cells were transfected with ARR2-LUC reporter and infected with lentiviruses encoding shRNAs for control (shCon, black bars) or RNF6
(shRNF6, white bars). After serum starvation, cells were pretreated with the indicated doses of dihydrotestosterone (DHT) for 16 hr before luciferase activity was274 Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc.
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RNF6 Regulates AR Transcriptional Activity(Figure 4A). Alignments of AR sequences from various species
showed that K845 and K847 were highly conserved
(Figure 4B), implying the functional importance of these two
residues. Substitution of K845 with an arginine residue (K845R
mutation) completely abolished AR polyubiquitination even in
the presence of RNF6, while K847R mutation only partially
reduced AR polyubiquitination, possibly due to the loss of the
K847 acceptor site (Figure 4C), suggesting that both lysines
are ubiquitinated but that ubiquitination of K845may be a prereq-
uisite for efficient ubiquitination of K847 and may play a more
important role in regulation of AR activity. This result was
supported by reporter assays demonstrating that the
AR-K845R mutant completely failed to be activated by RNF6
while the AR-K847R mutant functioned similarly to the wild-
type AR (Figure 4D). Thus, ubiquitination of K845 is essential
for AR transcriptional activity promoted by RNF6.
To study the physiological role of the ubiquitinated AR under
conditions similar to the natural milieu, we replaced endogenous
AR in LNCaP cells with the mutant AR lacking the ubiquitin
acceptor site using a strategy described previously (Guo et al.,
2006). As shown in Figure 4E, the transcriptional activity of the
replaced codon-switched wild-type AR (ARcs-WT), but not the
ARcs-K845R mutant, was enhanced by overexpression of
RNF6 under the serum-free condition. Real-time PCR analysis
was also carried out to compare the effects of ARcs-K845R
with ARcs-WT on several AR target genes. Consistent with the
microarraydataobtained in theRNF6knockdowncells, the integ-
rity of K845 appeared to be required for expression of both PSA
andRLN1 genes, but not for TMPRSS2 (Figure 4F). Furthermore,
the reChIP assay using anti-ubiquitin in AR-replaced LNCaPcells
demonstrated that the K845Rmutation abolished the capacity of
AR binding to a subset of AR-responsive genes (Figure 4G),
which was also consistent with the ChIP results obtained in
RNF6 knockdown cells. Taken together, these data suggest
that RNF6-mediated polyubiquitination at AR-K845 is required
for AR recruitment to a subset of AREs and thus modulates tran-
scription of the cognate target genes.
Ubiquitination of AR Is Required for Recruitment
of AR and Its Cofactor to a Subset of AREs
As the ubiquitination acceptor site of AR is located within the
ligand-binding domain (also known as the AF2 domain), mutationof K845 may affect its ligand binding and/or transactivation
activity associated with the AF2 domain. However, it is unlikely
that the K845Rmutation compromises the ligand binding activity
because the ARK845R mutant still responded to DHT treatment
and translocated into the nucleus upon ligand stimulation as the
wild-type AR did (Figure S5). Because RNF6-induced ubiquitina-
tion of AR modulates androgen-responsive genes by facilitating
its binding to a subset of ARE sites, we hypothesized that this
posttranslational modification may be necessary for AR binding
to its coactivators that interact specifically with AR at its
C-terminal region through the polyubiquitin chains. We then
tested whether ubiquitination of AR plays a role in the recruit-
ment of cofactors, especially those containing ubiquitin-
interacting domains such as ARA54. ARA54 is a member of the
RING finger B box protein family (Ito et al., 2001) that interacts
with the C-terminal portion of AR (aa 652–919) and enhances
androgen-dependent transactivation of AR (Kang et al., 1999).
The hydrophobic segments flanking the ring between ring fingers
(RBR) region of ARA54 cooperate with the conserved domain for
ubiquitin binding (Eisenhaber et al., 2007). It is possible that
ARA54 may interact with AR through the polyubiquitin chain
at the C-terminal ligand-binding domain. This possibility is sup-
ported by our observation that the association between AR
and endogenous ARA54 was completely abolished in CWR-R1
cells either when RNF6 was knocked down (Figure 5A) or when
endogenous AR was replaced with the ARcs-K845R mutant
(Figure 5B). Since ARA54 is reported to promote transactivation
of AR in an androgen-dependent manner, we examined whether
overexpression of RNF6 is sufficient to enhance ARA54 coacti-
vator activity for AR in the absence of ligand. Figure 5C shows
that, consistent with previous reports, ARA54 alone did not
promote AR activity in the absence of hormone, while a syner-
gistic increase of AR activity was detected in cells expressing
both ARA54 and RNF6 together compared to either one alone.
This increase appeared to depend on the integrity of the ubiquitin
acceptor site K845, as the AR-K845R mutant was not affected
under these conditions. Furthermore, the ChIP assay again
demonstrated that the recruitment of ARA54 to a subset of
AREs was dependent on ubiquitination of K845 (Figure 5D).
These data strongly suggest that RNF6-induced ubiquitination
of AR K845 functions as the scaffold to recruit its coactivators
such as ARA54.measured. Results are presented as mean relative LUC units ± SD of triplicate samples. *p < 0.01, **p < 0.005, ***p < 0.001. Right: expression of RNF6 in LNCaP
and CWR-R1 cells.
(C) CWR-R1 and C4-2B cells were infected with lentiviruses encoding shRNAs for control vector (shCon) orRNF6 (shRNF6). After serum starvation for 16 hr, cells
were lysed and subjected to immunoprecipitation with anti-AR under denaturing conditions, followed by western blotting with the indicated antibodies.
(D) COS-1 cells were transfected with PSA-LUC reporter together with AR, wild-type RNF6 (RNF6), or RING-deletion mutant (RNF6DR). Cells were maintained in
serum-free media for 16 hr before luciferase activity was measured. Results are presented as mean relative LUC units ± SD of triplicate samples.
(E) LNCaP cells were transfected with ARR2-LUC reporter, together with increasing doses of wild-type RNF6 (RNF6) or RING-deletion mutant (RNF6DR). Cells
were serum-starved for 16 hr before luciferase activity was measured. Results are presented as mean relative LUC units ± SD of triplicate samples. *p < 0.001.
(F) LNCaP cells were left untreated (NT) or infected with lentiviruses encoding shRNAs for either control (shCon) or RNF6 (shRNF6). At 16 hr postinfection, cells
were incubated in phenol red-free medium with 5% charcoal-stripped FBS and pretreated with (+DHT) or without (DHT) 1 nM DHT for 16 hr. RNAs were then
extracted and microarray assay was performed as described in Supplemental Experimental Procedures.
(G) LNCaP cells were infected with lentiviruses encoding shRNAs for control vector (shCon) or RNF6 (shRNF6). After serum starvation for 16 hr, LNCaP cells were
treated with 10 nM DHT for 1 hr before ChIP assay was carried out to examine the binding of AR to the androgen-responsive elements (AREs) located in the
regulatory region of PSA, RLN1, TMPRSS2, and BMF. PCR products amplified from the input and immunoprecipitation with control antibody (IgG) and anti-
AR (AR) were resolved on agarose gels.
(H) LNCaP cells were serum-starved for 16 hr before reChIP assay was performed using anti-AR followed by anti-RNF6. The recruitment of the protein complex to
the promoter (AREI/II) or enhancer (AREIII) regions of PSA, RLN1, BMF or TMPRSS2 was tested. PCR products from the input, immunoprecipitation with control
antibody (IgG), first-round ChIP with anti-AR (AR), and immunoprecipitation with experimental antibodies (reChIP) were resolved on agarose gels.
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RNF6 Regulates AR Transcriptional ActivityFigure 4. RNF6-Induced Polyubiquitination of AR at K845 and K847
(A) Tandem mass spectrometry (MS/MS) spectrum of AR peptide showing ubiquitination at K845 and K847. K* indicates lysine residues that are ubiquitinated.
(B) Alignment of AR protein sequences. K845 and K847 (boxed) are evolutionarily conserved across different species.
(C) COS-1 cells were transfected with wild-type AR (AR) or AR mutants (K845R and K847R), together with RNF6. At 36 hr posttransfection, cells were lysed and
subjected to immunoprecipitation using anti-AR under denaturing conditions. Immunoblotting was performed using the indicated antibodies.
(D) Top: COS-1 cells were transfected with ARR2-LUC reporter and the indicated plasmids. After serum starvation for 16 hr, luciferase activity was measured.
Results are presented as mean relative LUC units ± SD of triplicate samples. Bottom: expression of wild-type AR and AR mutants.
(E) Left: following AR replacement, LNCaP cells were transfected with ARR2-LUC reporter and serum-starved for 16 hr before luciferase activity was measured.
Results are presented as mean relative LUC units ± SD of triplicate samples. Right: AR or ARmutant expression in these cells wasmonitored by western blotting.
(F) Following AR replacement, LNCaP cells were serum-starved and then treated with 1 nMDHT for 16 hr. Total RNA was extracted and subjected to quantitative
real-time RT-PCR. Results are presented as mean values ± SD of three independent experiments.
(G) Following AR replacement, LNCaP cells were serum-starved for 16 hr and then pretreated with 1 nM DHT for 1 hr before reChIP assay was performed using
anti-Ub followed with anti-FLAG. Binding of AR to the promoter (AREI/II) or enhancer (AREIII) regions of PSA, RLN1, and TMPRSS2 was tested. PCR products
from input and immunoprecipitation with control antibody (IgG) and experimental antibodies (reChIP) were resolved on agarose gels.276 Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc.
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Progression and Required for Tumor Growth
To obtain more insights into the role of RNF6 in prostate
carcinoma development, we performed immunohistochemistry
(IHC) analysis on human prostate tissue arrays containing
36 benign, 233 hormone-naive, and 18 hormone-refractory
samples. RNF6 was detected in both nucleus and cytoplasm
of luminal epithelial cells. As summarized in Figure 6A, the
Figure 5. RNF6-Induced Polyubiquitination of AR
Facilitates Its Binding to Coactivators on a Subset
of AREs
(A) CWR-R1 cells were infected with lentiviruses encoding
shRNAs specific for control vector (shCon) or RNF6 (shRNF6).
Immunoprecipitation was performed using anti-ARA54
followed by immunoblotting with the indicated antibodies.
(B) Following AR replacement, immunoprecipitation was
carried out in CWR-R1 cells using anti-ARA54 antibody
followed by immunoblotting with the indicated antibodies.
TCL, total cell lysates.
(C) COS-1 cells were transfected with ARR2-LUC reporter and
the indicated plasmids, and cells were serum-starved for 16 hr
before luciferase activity was measured. Results are pre-
sented as mean relative LUC units ± SD of triplicate samples.
(D) Following AR replacement, LNCaP cells were serum-
starved for 16 hr before ChIP assay was performed using
anti-FLAG followed by anti-ARA54. Binding of AR and ARA54
to the promoter (AREI/II) or enhancer (AREIII) regions of PSA,
RLN1, or TMPRSS2 was tested. PCR products from input
and immunoprecipitationwithcontrol antibody (IgG) andexper-
imental antibodies (reChIP) were resolved on agarose gels.
Figure 6. Expression of RNF6 Is Associated with
Progression of Prostate Cancer
(A) Statistical analysis of human prostate tissue arrays stained
with anti-RNF6. Immunostaining scores (mean ± SD) for RNF6
in benign epithelium (N), hormone-naive (HN), and hormone-
refractory (HR) prostate tissues are summarized. Numbers in
parentheses represent sample sizes; numbers above the
bars in the right panel represent the percentage of positive-
staining cases (+%). Statistical differences were determined
by Wilcoxon’s rank-sum test.
(B) Representative fields of human prostate tissue arrays.
Immunohistochemical staining was performed using anti-
RNF6 antibody.
mean score for nuclear staining of RNF6 in
hormone-refractory samples (2.1944 ± 0.5884)
was significantly higher than that in benign
(0.0278 ± 0.0278) and hormone-naive (0.2586 ±
0.0502) samples (p < 0.001). Meanwhile, the
frequency of detection of RNF6-positive nuclear staining
increased dramatically in hormone-resistant tissues (50%)
compared to the benign (2.78%) and hormone-naive (14.16%)
samples. The changes in cytoplasmic staining of RNF6 followed
a pattern similar to that of the nuclear staining. Figure 6B shows
representative fields of the human prostate tissue arrays. Taken
together, these data suggest that RNF6 is significantly upregu-
lated in prostate cancer, especially in hormone-resistantCancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc. 277
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a close correlation with prostate cancer progression.
To test whether the overexpressed RNF6 in hormone-
refractory prostate cancer cells is required for tumor cell growth
under androgen-depleted conditions, RNF6 expression was
knocked down by specific shRNA in C4-2B and CWR-R1 cells.
Figure 7A shows that growth of these cells in androgen-depleted
media was significantly attenuated. Such growth inhibition was
also observed in xenograft models in castrated immunodeficient
mice (Figure 7B). These data indicate that RNF6 is required for
prostate tumor cell growth in both cell culture and xenograft
models under androgen-depleted conditions.
To further demonstrate that the effect of RNF6 on tumor growth
is mediated through modification of K845 of AR, we substituted
endogenous AR in CWR-R1 cells with either ARcs-WT or ARcs-
K845R mutant, and tumor growth was examined in castrated
male nude mice. As shown in Figure 7C, growth of CWR-R1 cells
expressing ARcs-K845R was dramatically compromised com-
pared to that of cells expressingARcs-WT. This growth retardation
was accompanied by a reduction in ubiquitination of the ARcs-
Figure 7. RNF6 Is Required for Prostate
Cancer Cell Growth under Androgen-
Depleted Conditions
(A) Prostate cancer cells were infected with lentivi-
ruses encoding shRNAs specific for the control
vector (shCon) or RNF6 (shRNF6-1 and -2). At
16 hr postinfection, cells were incubated in fresh
phenol red-freemediumwith5%charcoal-stripped
FBS and maintained for 7–10 days. Cell colonies
were visualized by Coomassie blue staining.
(B) CWR-R1 (left graph) and C4-2B (right graph)
were infected with lentiviruses encoding shRNAs
specific for the control vector (shCon) or RNF6
(shRNF6). At 48hr postinfection, cellswere injected
into left (shCon) and right (shRNF6) flanks of cas-
trated male nude mice. Growth of tumors was
examined as described in Experimental Proce-
dures. Results represent mean tumor sizes ± SD
(n = 5mice per group). *p < 0.05, **p < 0.001. Right:
expression of RNF6 in CWR-R1 and C4-2B cells.
(C) Left: following AR replacement, CWR-R1 cells
expressing ARcs-WT (d) or ARcs-K845R (B) were
injected into castrated male nude mice. Tumor
volume was measured as described in Experi-
mental Procedures. Results represent mean tumor
volume±SD (n=5micepergroup). *p<0.05.Right:
immunoprecipitation with anti-AR antibody using
xenograft mouse tissues, followed by immunoblot-
ting with antibodies as indicated.
K845R mutant in tumors, while the levels
ofARproteinappeared tobesimilar.Taken
together, our datademonstrate thatRNF6-
induced ubiquitination of AR at K845 is
important for prostate cancer cell growth
under androgen-depleted conditions.
DISCUSSION
Modulation of AR activity by various post-
translational modifications has been
extensively studied. Polyubiquitination of AR induced by
MDM2 has been shown to have a profound impact on the
stability and turnover of AR. In this report, we have demonstrated
that AR transcriptional activity and specificity are regulated by an
atypical polyubiquitination induced by RNF6. The RNF6-induced
AR polyubiquitination appears to be different from the previously
reported MDM2-mediated ubiquitin modification. One possible
explanation for this noncanonical function of ubiquitination is
the different topology of polyubiquitin chains induced by RNF6.
RNF6 appears to preferentially promote the assembly of K6-
and K27-mediated polyubiquitination of AR, possibly through
partnering with an E2 enzyme different from that for the LIMK1
substrate. The K6/27-mediated ubiquitin chains have recently
been shown to play a nonproteolytic function (Ben-Saadon
et al., 2006), and the K6-mediated ubiquitin chain is known to
prevent modified substrate from degradation (Shang et al.,
2005). This observation may explain at least in part why RNF6-
induced ubiquitination does not lead to AR degradation as
MDM2-induced ubiquitination does. Although RNF6 is able to
confer K48-mediated polyubiquitination of LIMK1 and induces278 Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc.
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ciable level of K48-mediated polyubiquitination of AR and asso-
ciated degradation. It is possible that RNF6 may partner with
a different E2 for distinct substrates in various cell contexts.
The role of ubiquitination in transcription regulation has been
demonstrated previously, such as in the cases of p53 (Le Cam
et al., 2006) and Met4 (Kaiser et al., 2000). In both cases, ubiqui-
tination of these transcription factors does not lead to protein
degradation but rather modulates their binding capacity with
chromatin or cofactors. Here, we have added another example,
the proteolysis-independent transactivation of AR by RNF6-
induced polyubiquitination, implying that polyubiquitination is
a general mechanism by which transcriptional factors are regu-
lated. The biochemical mechanisms bywhich this mixed branch-
ing chain enhances AR transcriptional activity remain to be ad-
dressed. Nevertheless, it would be reasonable to postulate
that the chain may serve as a docking site for recruitment of
important transcriptional activators such as ARA54. This func-
tion of the polyubiquitin chain as a recognition motif has also
been reported for the K63-based polyubiquitin chain, which is
essential for the activation of NF-kB pathway instead of protein
degradation (Ea et al., 2006). On the other hand, the effect of
RNF6 on AR transcriptional activity appears to be quite specific,
as RNF6 does not promote the activity of the closely related
nuclear receptor glucocorticoid receptor (GR) (Figure S6),
possibly due to the fact that the ubiquitin acceptor site K845
appears not to be conserved among the steroid hormone
nuclear receptor superfamily.
We have also demonstrated that RNF6 is upregulated in
hormone-refractory prostate cancer and may play an important
role in promoting prostate cancer growth under androgen-
depleted conditions. Our findings are supported by at least three
independent microarray studies in the publicly available Onco-
mine database (Rhodes et al., 2007) showing that expression
of RNF6 is significantly elevated during prostate cancer progres-
sion (Figure S7). These microarray analyses suggest that RNF6
may function as a potential oncogene in promoting prostate
cancer progression, especially to the androgen-independent
state. RNF6 may exert its biological activity at least in part by
preferentially regulating a subset of AR target genes that are
known to be involved in progression to the hormone-refractory
state. Deregulation of some of the genes regulated by RNF6
(e.g.,RLN1) has been shown to play a causal role in development
of hormone-refractory prostate cancer (Feng et al., 2007; Liu
et al., 2008; Wang et al., 2007). This observation is supported
by our microarray analysis and validation experiments including
real-time PCR and ChIP assays. In addition, our microarray anal-
ysis also uncovered that the androgen-suppressed gene BMF is
negatively regulated by RNF6. BMF is a BH3 domain-only
protein and a proapoptotic member of the BCL2 family of
proteins (Puthalakath et al., 2001) and is a key mediator of anoi-
kis and luminal cell death during mouse mammary acinar
morphogenesis (Schmelzle et al., 2007). Suppression of BMF
expression by RNF6 in prostate cancer cells may prevent
apoptosis induced by androgen ablation and promote
hormone-independent growth. Although somatic mutations of
RNF6 have been detected in some primary esophageal squa-
mous cell carcinomas and cell lines (Lo et al., 2002), it remains
to be determined whether these mutations affect RNF6 activity.It is possible that RNF6 may have both oncogenic and tumor-
suppressive effects, depending on the cellular context.
In addition, we have shown that RNF6 can induce polyubiqui-
tination at K845 of AR and that the assembled polyubiquitin
chains in the AF2 domain of AR may serve as a platform for
recruiting additional transcription coregulators that are required
for stabilization of the transcription complex and activation of
a subset of AR-regulated genes. One such coregulator is the
RING-finger protein ARA54, a ligand-dependent AR coactivator.
We showed that an RNF6-mediated polyubiquitin chain is
required for recruiting ARA54 to a subset of androgen-respon-
sive genes under androgen-depleted conditions. Mutation of
AR at K845 completely abolished binding of ARA54 to a subset
of AREs including those located in the regulatory region of
RLN1 and the distal ARE of PSA but had very minimal effects
on the AREs located in the regulatory region of TMPRSS2 and
the proximal AREs of PSA. These results suggest that RNF6-
induced polyubiquitination of AR may play a role in determining
promoter specificity of AR target genes. It is still unknown how
ubiquitination determines the selectivity of ARE binding. Besides
the specific coregulators binding to the polyubiquitin chains,
other aspects of the cellular microenvironment such as local
chromatin context and availability/accessibility of certain
cofactors are likely to be involved. ARA54 contains RING-like
sequence domains that lead to its autoubiquitination (Ito et al.,
2001), but its cellular substrates have yet to be identified. Here,
we demonstrated that ARA54 can promote the activity of AR
together with RNF6 under serum-free conditions, suggesting a
synergistic cooperation between these two cofactors. Such
a ubiquitination cascade may amplify androgen/AR signaling
and provide another layer of regulation of transcription magni-
tude and specificity. Based on the current study, our working
model is that RNF6 induces an atypical polyubiquitination of
AR, and this modification may serve as a platform to recruit addi-
tional coregulators containing the ubiquitin-interacting domain
(or domains) to facilitate transcriptional regulation of AR target
genes (Figure 8). Our work has suggested that ubiquitination is
one of the mechanisms by which AR transcription activity and
specificity are regulated. Such a mechanism may also be appli-
cable to regulation of other nuclear receptors. Given that RNF6 is
overexpressed in hormone-refractory prostate cancer and that
its activity is required for tumor cell growth under androgen-
depleted conditions, it may potentially be a new drug target for
treatment of advanced prostate cancer.
EXPERIMENTAL PROCEDURES
DNA Plasmid Constructs and Antibodies
Two human EST clones ofRNF6 (GI 12 769 059 and 22 815 435) were obtained
from American Type Culture Collection (ATCC). The full-length human RNF6
cDNA was amplified by PCR using the EST clones as the template and then
subcloned into pcDNA3-based vector. Mammalian expression constructs of
FLAG-tagged AR and its mutants were cloned as described previously (Kurita
et al., 2001). The GST fusion protein of AR C-terminal domains (aa 622–919)
was generously provided by E. Xu (Van Andel Research Institute). RNF6 and
AR mutants were generated by a PCR-based method using a QuikChange
kit (Stratagene) and confirmed by DNA sequencing. Mammalian expression
constructs of His6-ubiquitin molecules (both the wild-type and lysine-free
mutant) were generously gifts of W. Gu (Columbia University). The shRNAs
for AR and RNF6 were constructed as described previously (Guo et al.,Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc. 279
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AAACCTCAGTGAA-30 (shRNF6-1) and 50-GAGGCCTATTATCAGTTTA-30
(shRNF6-2). Antibodies used for immunoblotting, immunoprecipitation, and
immunofluorescence included anti-AR (N-20), anti-actin (C-2), anti-PSA
(A67-B/E3), anti-ubiquitin (P4D1), anti-ARA54 (H-300), anti-GAPDH, anti-
MDM2 (SMP14) (Santa Cruz), and anti-FLAG M2 (Sigma). The monoclonal
antibody for RNF6 (anti-RNF6) was developed by immunizing mice with a
purified fusion protein containing N-terminal residues of RNF6 (aa 1–246),
and hybridoma clones were isolated and maintained in RPMI 1640 medium
containing 25 mM HEPES (Invitrogen). The conditioned medium was used in
the study.
Cell Culture and Transfection
293T, COS-1, and all human prostate cancer cell lines except for CWR-R1
used in this study were purchased from ATCC. CWR-R1 was kindly provided
by C. Gregory and E. Wilson (University of North Carolina at Chapel Hill)
(Gregory et al., 2001). 293T and COS-1 cells were routinely maintained in
DMEM, while prostate cancer cells were cultured in RPMI 1640. Media were
supplemented with 10%FBS and 1%penicillin/streptomycin unless otherwise
specified. Transfections were performed using FuGENE HD (Roche) or the
calcium phosphate precipitation method (Biological Mimetics, Inc.) according
to the manufacturer’s instructions.
In Vitro Ubiquitination Assay
In vitro ubiquitination assay was carried out as described previously (Fang
et al., 2000; Guan et al., 2008), with minor modifications. Briefly, 10 ng of
purified GST-ARc was mixed with 300 ng of either ligase-active GST-RNF6
(aa 246–685) or ligase-inactive GST-RNF6 (aa 1–585) in a total volume of
30 ml containing 50 mM HEPES (pH 7.9), 4 mM ATP, 5 mM MgCl2, 15 mM
ZnCl2, 150 mM ubiquitin (Boston Biochem, cat. #U-100H), 30 nM rabbit E1
(Boston Biochem, cat. #E302), and 200 nM UbcH5a (Boston Biochem, cat.
#E2-616). The reaction was incubated at 37C for 4 hr, and reactions
were terminated by addition of SDS sample buffer. Samples were resolved
by SDS-PAGE and immunoblotted with anti-AR antibody (C-19). In some
experiments, ubiquitin was replaced with a lysine null mutant (K0) or a
Figure 8. A Postulated Model of Regulation of AR Activity by RNF6
Our working model is that RNF6-induced ubiquitination of AR may serve as
a scaffold for cofactor recruitment. Step 1: RNF6 binds to AR and induces
polyubiquitination of the AF2 domain of AR in a RING domain-dependent
manner. Step 2: the RNF6-induced polyubiquitin chain facilitates the recruit-
ment of AR coactivators containing ubiquitin-binding domains (UBDs) and
stabilizes the transcription complex at a subset of ARE sites in a polyubiqui-
tin-dependent manner. Step 3: the polyubiquitination-dependent complex
modulates transcription of AR-targeted genes. The E2 or E2s involved in this
process have yet to be identified.280 Cancer Cell 15, 270–282, April 7, 2009 ª2009 Elsevier Inc.single-lysine-containing mutant (K6, K11, K27, K29, K33, K48, and K63)
(Boston Biochem) as indicated in the figures. In some cases, the E2 UbcH5a
was replaced with UbcH2, UbcH10, or Use1 (Boston Biochem) as indicated
in the figures.
Chromatin Immunoprecipitation
LNCaP cells were cultured in complete RPMI 1640 medium and infected for
24 hr with lentiviral constructs as indicated in figure legends. After serum star-
vation for 16 hr, cells were pretreated as described in the figure legends before
being crosslinked with 1% formaldehyde and then sonicated. Soluble
chromatin was immunoprecipitated as described previously (Louie et al.,
2003; Shang et al., 2002). Primers used for ChIP were PSA promoter ARE
(AREI/II), 50-AGGGATCAGGGAGTCTCACA-30 and 50-GCTAGCACTTGCTGTT
CTGC-30; PSA enhancer ARE (AREIII), 50-ACAGACCTACTCTGGAGGAAC-30
and 50-AAGACAGCAACACCTTTTT-30; TMPRSS2, 50-TGGTCCTGGATGATA
AAAAAAGTTT-30 and 50-GACATACGCCCCACAACAGA-30 (Wang et al.,
2007); RLN1, 50-GAGAGTCCCAAAGGCTAGCAGAG-50 and 50-GAACTTC
CTCGGCTTCTGTTTGG-30; BMF, 50-GCTGGAGTGCACCACCTCAC-30 and
50-CCAGAAGCAGCAACCACCTG-30.
ReChIP analysis was performed as described previously (Mal and Harter,
2003). Briefly, first-round antibody was added to chromatin extracts and incu-
bated overnight at 4C followed by addition of 60 ml salmon sperm/protein A
agarose (Upstate Biotechnology) to recover immunocomplexes. The bound
protein complexes were eluted by 10 mM dithiothreitol (DTT) at room temper-
ature for 30 min, and the elution was then diluted ten times with reChIP buffer
(1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris [pH 8.1]) and
subsequently reimmunoprecipitated by addition of the second-round or
control IgG antibodies overnight at 4C. Recovery and preparation of DNA
was performed and followed by PCR using the oligonucleotides described
above.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was performed as described previously
(Zhang et al., 2005). Primer sequences used were PSA, 50-TCTGCGGCG
GTGTTCTG-30 and 50-GCCGACCCAGCAAGATCA-30 (Patel et al., 2004);
TMPRSS2, 50-GGACAGTGTGCACCTCAAAGAC-30 and 50-TCCCACGAGGA
AGGTCCC-30 (Wang et al., 2007); RLN1, 50-CGGCCAAATGGAAGGAC-30 and
50-GTGGCAAATTAGCAATGAATTCCA-30; BMF, 50-GAGGTACAGATTGCCC
GAAA-30 and 50-TTCAAAGCAAGGTTGTGCAG-30; andActin, 50-GCTATCCAG
GCTGTGCTATC-30 and 50-TGTCACGCACGATTTCC-30. The relative abun-
dance of each target transcript was quantified using the comparative DDCt
method, with Actin as an internal control.
Immunohistochemical Analysis
Several intermediate-density prostate tissue arrays were prepared by the NYU
Cooperative Prostate Cancer Tissue Resource. These arrays contained
287 cases, including 18 hormone-refractory (HR) and 18 age- and Gleason-
matched hormone-naive (HN) transurethral resection (TURP) prostate speci-
mens from patients with clinically advanced prostate cancer, 36 cases of
non-tumor-containing tissue from patients with benign prostatic hypertrophy,
and 215 radical prostatectomy cases representing additional HN prostate
cancer cases. The determination of HR versus HN was as follows: patients
who had previously undergone surgical orchiectomy or medical hormone-
suppressive therapy at least 6 months prior to the procedure were considered
as HR, and patients who did not receive hormonal therapy prior to the TURP or
radical prostatectomy were considered as HN. Tissue specimens were from
the archival paraffin block inventory of the NYU Cooperative Prostate Cancer
Tissue Resource. All cases were collected into the resource under an Institu-
tional Review Board-approved protocol and underwent repeated pathological
characterization of tissues and review of medical records. A Vectastain Elite
ABC Kit (Vector Laboratories) was used for immunohistochemical staining
according to the protocol recommended by the manufacturer. Immunostain-
ing was evaluated manually and graded using a two-score system based on
intensity score (IS) and proportion score (PS) as described previously (Harvey
et al., 1999). The immunoreactive score for each case was quantified by the
average of four cores. Statistical analyses were carried out using SAS version
9.1 statistics software.
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in Xenograft Models
Prostate cancer cells were cultured in complete RPMI 1640 and infected with
lentiviruses encoding shRNAs specific for RNF6 or GFP control. After 48 hr,
cells were maintained in fresh phenol red-free RPMI 1640 medium with 5%
charcoal-stripped FBS and allowed to grow for 7–10 days. The cells were
then fixed with 1% formaldehyde and stained with Coomassie blues. Tumor
growth in SCID/nude mice was monitored as described previously (Craft
et al., 1999). All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of the University of Maryland.
Tumor cells were allowed to grow in 5–10 intact or castrated male mice for
4–10 weeks until the tumors reached a volume of 300 mm3. Tumor volume
was calculated by the formula 0.5236 3 r1
2 3 r2 (where r1 < r2) (Long et al.,
2000).
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